Trial · NCT07897903
Group Cognitive Processing Therapy for Women Survivors of Gender-Based Violence: Feasibility Study
NCT07897903, Not applicable, Not yet recruiting, Universidad Complutense de Madrid
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Group Cognitive Processing Therapy for Women Survivors of Gender-Based Violence: Feasibility Study. Trials, record NCT07897903. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07897903
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Group Cognitive Processing Therapy for Women Survivors of Gender-Based Violence: Feasibility Study
- NCT number
- NCT07897903
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 10 participants, estimated
- Lead sponsor
- Universidad Complutense de Madrid
- Conditions
- Trauma, Psychological, Traumatic Stress Disorder
- Interventions
- Group CPT + TAU (Experimental)
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment retention/adherence | At the beginning of each session (all 12 weeks) | Proportion of enrolled participants who complete the intervention (participants retention/adherance \>= 75%). |
| Primary | Recruitment rate | Recruitment period | Participants enrolled |
| Primary | Mean number of sessions attended and attrition rate | At the beginning of each session (all 12 weeks) | |
| Primary | Client Satisfaction Questionnaire | Immediately after the intervention (week 12) | Acceptability will be assessed after the intervention using a participant satisfaction questionnaire (CSQ-8). The questionnaire will evaluate participants' perceived usefulness, relevance, comprehensibility, and overall satisfaction with the intervention. 8 items rated from 1 to 4. Total score ranges from 8 to 32. Higher scores indicate greater satisfaction and acceptability (better outcome). |
| Secondary | Change in PTSD/CPTSD symptoms (I) at 12 weeks and 6 months | Baseline, at the beginning of each session, end of treatment (week 12), and 6-month follow-up | PTSD Checklist for DSM-5 (PCL-5; Weathers et al., 2013). * 20 items rated from 0 (not at all) to 4 (extremely). Total score ranges from 0 to 80. * Higher scores indicate a worse outcome (more severe symptoms). |
| Secondary | Change in PTSD/CPTSD symptoms (II) at 12 weeks and 6 months | Baseline, end of treatment (week 12), and 6-month follow-up | International Trauma Questionnaire (ITQ; Cloitre et al., 2018). * 12 symptom items (6 PTSD, 6 Disturbances in Self-Organization) rated from 0 (not at all) to 4 (extremely). Symptom total score ranges from 0 to 48 (each of the two sets of items from 0 to 24). * Higher scores indicate a worse outcome (more severe symptoms). |
| Secondary | Change in PTSD/CPTSD symptoms (III) at 12 weeks and 6 months | Baseline, end of treatment (week 12), and 6-month follow-up | Impact of Trauma Questionnaire (Spanish questionnaire; "Cuestionario de Impacto del Trauma", CIT; Crespo, González-Ordi, Gómez-Gutiérrez, Santamaría, 2020). * 180 items related to different scales on PTSD symptomatology and comorbid symptomatology rated from 1 (never) to 5 (always). * Higher scores mean worse outcome (more severe symptoms). |
| Secondary | Change from psychopathological symptoms at 12 weeks and 6 months | Baseline, end of treatment (week 12), and 6-month follow-up | Symptom Assessment-45 Questionnaire (SA-45; Davison et al., 1997), a brief version of the Symptom Checklist-90-Revised (SCL-90-R). * 45 items rated from 0 (not at all) to 4 (a lot). It covers a total of 9 different symptomatic areas (e.g. depression, anxiety, interpersonal sensibility) and gives an overall severity score. Total score ranges from \[0 to 180\]. * Higher scores indicate a worse outcome (more severe symptoms). |
| Secondary | Change from Well-being at 12 weeks and 6 months | Baseline, end of treatment (week 12), and 6-month follow-up | Ryff's Scales of Psychological Well-Being (Ryff \& Keyes, 1995). * 29 items rated from 1 (strongly disagree) to 6 (strongly agree). The SPWB evaluates 6 dimensions of psychological well-being: Self-acceptance, Positive relationships, Autonomy, Environmental mastery, Life purpose, and Personal growth. Scores ranges differ from scale to scale: * Self-acceptance \[4-24\] * Positive relationships \[5-30\] * Autonomy \[6-36\] * Environmental mastery \[5-30\] * Life purpose \[4-24\] * Personal growth \[5-30\] * Higher scores indicate a better outcome (more psychological wellbeing). |
| Secondary | Change from Satisfaction with life at 12 weeks and 6 months | Baseline, end of treatment (week 12), and 6-month follow-up | Satisfaction with Life Scale (SWLS; Diener et al., 1985). * 5 items rated from 1 (strongly disagree) to 7 (strongly agree). Total score ranges from 5 to 35. * Higher scores indicate a better outcome (more satisfaction with life). |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07897903
GET https://conductscience.org/api/trials/v1/NCT07897903/registered